Anil Kapoor

16.0k total citations · 2 hit papers
403 papers, 9.9k citations indexed

About

Anil Kapoor is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Anil Kapoor has authored 403 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Pulmonary and Respiratory Medicine, 157 papers in Molecular Biology and 113 papers in Surgery. Recurrent topics in Anil Kapoor's work include Renal cell carcinoma treatment (184 papers), Renal and related cancers (108 papers) and Bladder and Urothelial Cancer Treatments (81 papers). Anil Kapoor is often cited by papers focused on Renal cell carcinoma treatment (184 papers), Renal and related cancers (108 papers) and Bladder and Urothelial Cancer Treatments (81 papers). Anil Kapoor collaborates with scholars based in Canada, United States and Italy. Anil Kapoor's co-authors include Robert A. Figlin, Michael A. Carducci, Piotr Tomczak, Elżbieta Starosławska, Laurence Moore, Timothy E. O’Toole, Damu Tang, Robert J. Motzer, Janice Dutcher and Gary R. Hudes and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Anil Kapoor

382 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

2007 2.8k citations Robert A. Figlin, Anil Kapoor et al. profile →
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline

2019 291 citations Anil Kapoor et al. profile →

Peers

Countries citing papers authored by Anil Kapoor

Since Specialization

Citations

This map shows the geographic impact of Anil Kapoor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anil Kapoor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anil Kapoor more than expected).

Fields of papers citing papers by Anil Kapoor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anil Kapoor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anil Kapoor. The network helps show where Anil Kapoor may publish in the future.

Co-authorship network of co-authors of Anil Kapoor

This figure shows the co-authorship network connecting the top 25 collaborators of Anil Kapoor. A scholar is included among the top collaborators of Anil Kapoor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anil Kapoor. Anil Kapoor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluating Long-Term Oncologic Outcomes of Radiofrequency Ablation for T1a Renal Cell Carcinoma with Minimum 10 Years of Follow-Up 2025 ·Journal of Endourology ·(unknown), (unknown), Alan Cheng, Labib Syed, (unknown), Edward D. Matsumoto, Anil Kapoor, (unknown)	0
2	Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening 2024 ·JCO Precision Oncology ·(unknown), Mikiko Endo, Yoshiaki Usui, Yusuke Iwasaki, Rodney H. Breau, Anil Kapoor, Mark Lathrop, Simon Tanguay, Yukihide Momozawa, Yasser Riazalhosseini	1
3	Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States 2023 ·Annals of Epidemiology ·Cristina Cano Garcia, (unknown), Mattia Luca Piccinelli, Stefano Tappero, Andrea Panunzio, Francesco Barletta, Reha‐Baris Incesu, Zhe Tian, Fred Saad, Anil Kapoor, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Derya Tilki, Alessandro Antonelli, Ottavio De Cobelli, Luis A. Kluth, Andreas Becker, Felix K.‐H. Chun, Pierre I. Karakiewicz	4
4	Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer 2023 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), (unknown), Anil Kapoor, Paweł Zalewski, Neil Fleshner, Edward Chow, Urban Emmenegger	5
5	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative 2021 ·Urologic Oncology Seminars and Original Investigations ·Benjamin Shiff, Rodney H. Breau, Ranjeeta Mallick, Frédéric Pouliot, Alan So, Simon Tanguay, Anil Kapoor, Jean‐Baptiste Lattouf, Luke T. Lavallée, Adrian Fairey, Antonio Finelli, Bimal Bhindi, Jun Kawakami, Ricardo Rendon, (unknown)	13
6	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System 2021 ·Clinical Genitourinary Cancer ·Igal Kushnir, Naveen S. Basappa, Sunita Ghosh, Aly‐Khan A. Lalani, Aaron R. Hansen, Lori Wood, Christian Kollmannsberger, Daniel Y.C. Heng, Georg A. Bjarnason, Denis Soulières, David E. Dawe, Simon Tanguay, Rodney H. Breau, Frédéric Pouliot, Anil Kapoor, Jeffrey Graham, M. Neil Reaume	12
7	Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma 2020 ·Clinical Cancer Research ·Robert A. Figlin, Nizar M. Tannir, Robert G. Uzzo, Scott S. Tykodi, David Y.T. Chen, Viraj A. Master, Anil Kapoor, Daniel A. Vaena, William T. Lowrance, Gennady Bratslavsky, Mark DeBenedette, (unknown), (unknown), (unknown), (unknown), Irina Y. Tcherepanova, Charles A. Nicolette, Christopher G. Wood	53
8	Management of complex renal cysts in Canada: results of a survey study 2020 ·BMC Urology ·Félix Couture, Antonio Finelli, Amélie Têtu, Bimal Bhindi, Rodney H. Breau, Anil Kapoor, Wassim Kassouf, Luke T. Lavallée, Simon Tanguay, Philippe D. Violette, Patrick O. Richard	4
9	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis 2019 ·Urologic Oncology Seminars and Original Investigations ·Madhur Nayan, (unknown), Anil Kapoor, Antonio Finelli, Alan So, Ricardo Rendon, Rodney H. Breau, Luke T. Lavallée, Simon Tanguay, Daniel Y.C. Heng, Jun Kawakami, Naveen S. Basappa, Georg A. Bjarnason, Frédéric Pouliot, Robert J. Hamilton	2
10	Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2 2019 ·Urologic Oncology Seminars and Original Investigations ·Emily C L Wong, (unknown), Rodney H. Breau, Frédéric Pouliot, Antonio Finelli, Luke T. Lavallée, Alan So, Simon Tanguay, Adrian Fairey, Ricardo Rendon, Patrick O. Richard, Jean‐Baptiste Lattouf, Jun Kawakami, Ranjeeta Mallick, Anil Kapoor	23
11	SDH-deficient renal cell carcinoma – clinical, pathologic and genetic correlates: a case report 2018 ·BMC Urology ·(unknown), Michael Bonert, Asghar Naqvi, Kevin Zbuk, Anil Kapoor	18
12	Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer 2016 ·Cancer Research ·Judy Yan, Diane Ojo, Anil Kapoor, Xiaozeng Lin, Jehonathan H. Pinthus, Tariq Aziz, Tarek A. Bismar, Fengxiang Wei, Nicholas Wong, Jason De Melo, Jean‐Claude Cutz, Pierre Major, Geoffrey A. Wood, Hao Peng, Damu Tang	40
13	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML) 2015 ·Urology ·Anil Kapoor, Louis Girard, Jean‐Baptiste Lattouf, York Pei, Ricardo Rendon, (unknown), Alan So	18
14	Contrast-enhanced Ultrasonography for Surveillance of Radiofrequency-ablated Renal Tumors: A Prospective, Radiologist-blinded Pilot Study 2015 ·Urology ·Christopher B. Allard, (unknown), Shawn Dason, (unknown), Bobby Shayegan, Edward D. Matsumoto, Anil Kapoor	17
15	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update 2013 ·Canadian Urological Association Journal ·Fred Saad, Sébastien J. Hotte, Charles Catton, Darrel Drachenberg, Antonio Finelli, Neil Fleshner, Martin Gleave, Anil Kapoor, Wassim Kassouf, Andrew Loblaw, Scott North, Nawaid Usmani, Kim N.	15
16	An alternative approach to deal with the absence of clinical trials: a proportional meta-analysis of case series studies 2013 ·Acta Cirúrgica Brasileira ·Regina El Dib, Paulo do Nascimento, Anil Kapoor	39
17	Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta‐analysis of case series studies 2012 ·British Journal of Urology ·Regina El Dib, Naji J. Touma, Anil Kapoor	145
18	Binding of Anti-GRP78 Autoantibodies to Cell Surface GRP78 Increases Tissue Factor Procoagulant Activity via the Release of Calcium from Endoplasmic Reticulum Stores 2010 ·Journal of Biological Chemistry ·Ali Al‐Hashimi, Jennifer Caldwell, Mario Gonzalez–Gronow, Salvatore V. Pizzo, (unknown), (unknown), (unknown), Jeffrey I. Weitz, Alan R. Stafford, Howard H.W. Chan, Anil Kapoor, Donald W. Jacobsen, Jeffrey G. Dickhout, Richard C. Austin	35
19	Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC) 2010 ·Drug Healthcare and Patient Safety ·Anil Kapoor, (unknown), (unknown)	1
20	Acute rejection and the flow cytometry crossmatch 1999 ·Transplantation Proceedings ·(unknown), Daniel Cook, (unknown), James F. McCarthy, (unknown), Anil Kapoor, MICHAEL G. HOBART, Stuart M. Flechner, Charles S. Modlin, David A. Goldfarb, Andrew C. Novick	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact